Hengrui Medicine gains approval for multiple clinical trials

Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiaries, Shandong Shengdi Pharmaceutical Co., Ltd., Suzhou Shengdiya Biomedical Co., Ltd., and Shanghai Shengdi Pharmaceutical Co., Ltd., have obtained approval from the National Medical Products Administration for clinical trials of HRS-7058 capsules/tablets, adetrelimab injection, bevacizumab injection, and SHR-1826 injection. The clinical trial for HRS-7058 will be a Phase II study evaluating its safety, tolerability, and efficacy in solid tumor subjects, in combination with anti-tumor drugs. The company notes the global market for Sotorasib and Adagrasib was approximately USD 4.85 billion in 2024. HRS-7058 has accumulated research and development investment of CNY 63.91 million. Clinical trials for Adetrelimab target cancers using PD-1/PD-L1 pathways with approximately USD 8.985 billion in global sales of related treatments during 2023. Bevacizumab had approximately USD 6.088 billion in global sales during 2023. The company has invested CNY 805.09 million in the clinical trials for Adetrelimab and CNY 333.49 million on clinical trials for Bevacizumab. Development costs for SHR-1826 have reached CNY 5.84 million. The company cautioned that the drug development process is lengthy and subject to uncertainty.